GleamWall
中文EN

INKT MiNK Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1840229 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY10.8%
TTM EPS YoY25.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-95.0%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets297.2%
Debt / equity—
Current ratio0.97x
Interest coverage317.82x

Cash quality & payout

Operating cash flow / net income0.65x
Accruals ratio-33.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$200,000———$0———
R&D expense$1.80M$1.89M$1.20M$1.51M$1.14M$1.84M$1.26M$1.41M
SG&A expense$1.03M$1.33M$1.68M$1.76M$1.85M$1.85M$1.27M$808,904
Operating income-$2.64M-$3.22M-$2.88M-$2.71M-$3.18M-$4.05M-$2.70M-$2.50M
Interest expense-$1,000-$2,000-$4,000-$29,000-$25,000-$27,000-$29,000-$30,000
Net income-$2.55M-$3.13M-$2.74M-$2.60M-$2.89M-$4.24M-$2.77M-$2.46M
EBITDA-$2.60M-$3.18M-$2.85M-$2.67M-$3.14M-$4.00M-$2.65M-$2.45M
EPS (basic)-0.50-0.62-0.57—-0.65-1.06-0.70—
EPS (diluted)-0.50-0.62-0.57—-0.65-1.06-0.70—
Weighted avg. shares (diluted)5.10M5.02M4.80M—4.44M3.98M3.96M—
Banking
Net interest income$72,323$72,884$80,834$111,230$55,151$348$13,517$39,573
Balance sheet
Cash & equivalents$7.47M$8.81M$9.53M$13.36M$14.28M$1.68M$3.23M$4.58M
Current assets$7.90M$9.30M$10.02M$13.85M$14.53M$2.01M$3.58M$4.99M
PP&E, net$339,160$318,474$354,518$390,869$429,344$473,215$687,500$732,929
Total assets$8.24M$9.62M$10.38M$14.24M$14.96M$2.48M$4.27M$5.72M
Current liabilities$8.18M$7.57M$7.29M$13.03M$13.43M$13.16M$12.12M$6.96M
Total liabilities$24.49M$23.64M$23.06M$28.47M$28.48M$27.67M$26.06M$25.31M
Shareholders' equity-$16.25M-$14.03M-$12.69M-$14.23M-$13.51M-$25.19M-$21.79M-$19.59M
Shares outstanding5.10M5.10M—4.71M———3.96M
Cash flow statement
Operating cash flow-$1.28M-$2.08M-$1.73M-$2.07M-$941,348-$1.57M-$1.34M-$1.73M
Financing cash flow$0$1.37M-$2.10M$1.18M$13.55M$540$576-$3
Depreciation & amortization$36,065$36,064$36,066$38,563$43,654$48,763$50,765$53,869
Stock-based compensation$333,000$422,000$630,386$565,771$621,000$897,000$591,089$390,048

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.